Open AccessCurrent Updates on the Management of AL Amyloidosis
Author(s) -
M. Taha ElSayed,
Sara Usher,
Muhammad Hamza Habib,
Nausheen Ahmed,
Ali H. Jawad,
Madeline Begemann,
Syed Ahmed Shabbir,
Leila Shune,
Jaffar Al-Hilli,
Furha Cossor,
Brett W. Sperry,
Shahzad Raza
Publication year - 2021
Publication title -
journal of hematology
Language(s) - English
Resource type - Journals
eISSN - 1927-1220
pISSN - 1927-1212
DOI - 10.14740/jh866
Subject(s) - amyloidosis , multiple myeloma , al amyloidosis , medicine , immunoglobulin light chain , amyloid (mycology) , disease , pathology , immunology , antibody
Systemic immunoglobulin light chain (AL) amyloidosis is a rare but fatal disease. It results from clonal proliferation of plasma cells with excessive production of insoluble misfolded proteins that aggregate in the extracellular matrix, causing damage to the normal architecture and function of various organs. For decades, treatment for AL amyloidosis was based mainly on therapeutic agents previously studied for its more common counterpart, multiple myeloma. As the prevalence and incidence of AL amyloidosis have increased, ongoing research has been conducted with treatments typically used in myeloma with varying success. In this review, we focus on current treatment strategies and updates to clinical guidelines and therapeutics for AL amyloidosis.